Anixa Biosciences Inc - Asset Resilience Ratio
Anixa Biosciences Inc (ANIX) has an Asset Resilience Ratio of 82.13% as of April 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Anixa Biosciences Inc's Asset Resilience Ratio has changed over time. Check how strategically is Anixa Biosciences Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Anixa Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Anixa Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.21 Million | 82.13% |
| Total Liquid Assets | $12.21 Million | 82.13% |
Asset Resilience Insights
- Very High Liquidity: Anixa Biosciences Inc maintains exceptional liquid asset reserves at 82.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anixa Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Anixa Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Anixa Biosciences Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Anixa Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 86.63% | $13.93 Million | $16.08 Million | +0.24pp |
| 2024-10-31 | 86.39% | $18.65 Million | $21.59 Million | -3.45pp |
| 2023-10-31 | 89.84% | $22.93 Million | $25.52 Million | +32.87pp |
| 2022-10-31 | 56.97% | $17.33 Million | $30.41 Million | +38.77pp |
| 2021-10-31 | 18.20% | $6.60 Million | $36.26 Million | -9.73pp |
| 2020-10-31 | 27.93% | $2.64 Million | $9.45 Million | -9.41pp |
| 2019-10-31 | 37.34% | $2.35 Million | $6.29 Million | +6.32pp |
| 2018-10-31 | 31.01% | $2.00 Million | $6.45 Million | -8.70pp |
| 2017-10-31 | 39.72% | $3.50 Million | $8.81 Million | +26.39pp |
| 2016-10-31 | 13.33% | $750.00K | $5.63 Million | -12.38pp |
| 2015-10-31 | 25.71% | $2.40 Million | $9.34 Million | -1.90pp |
| 2014-10-31 | 27.61% | $2.50 Million | $9.06 Million | +18.78pp |
| 2012-10-31 | 8.83% | $500.00K | $5.66 Million | -17.18pp |
| 2011-10-31 | 26.01% | $2.25 Million | $8.65 Million | +18.40pp |
| 2009-10-31 | 7.61% | $749.94K | $9.85 Million | -11.62pp |
| 2008-10-31 | 19.24% | $1.44 Million | $7.50 Million | -2.15pp |
| 2007-10-31 | 21.39% | $400.00K | $1.87 Million | +19.35pp |
| 2006-10-31 | 2.04% | $38.00K | $1.86 Million | -25.31pp |
| 2005-10-31 | 27.35% | $401.00K | $1.47 Million | +25.94pp |
| 2000-10-31 | 1.41% | $96.87K | $6.89 Million | -4.77pp |
| 1999-10-31 | 6.17% | $500.00K | $8.10 Million | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more